FRISC II TRIAL PDF!
The FRISC-II trial was the first randomised trial to show a reduction in death or myocardial infarction with an early invasive versus a. Contribution to the Literature: The FRISC-II trial showed that early invasive therapy reduced the incidence of death or myocardial infarction (MI). The FRISC II trial was the first to show that an early aggressive (invasive) treatment was superior to ini- tial conservative (non-invasive) therapy in patients with.
|Published:||20 October 2016|
|PDF File Size:||34.81 Mb|
|ePub File Size:||40.52 Mb|
The FRISC-II trial was the first randomised trial to show a reduction in death or myocardial infarction with an early invasive versus frisc ii trial non-invasive treatment strategy in patients with non-ST-elevation acute coronary syndrome.
Frisc ii trial we provide a remaining lifetime perspective on the effects on all cardiovascular events during 15 years' follow-up.
The rate of myocardial infarction was significantly lower in the invasive group 7. All patients were treated with aspirin, statin, beta-blockers, and ACE inhibitors according to treatment guidelines.
At 6 months, the composite of death or MI was significantly lower in the invasive group 9. At 5 years, the differences remained between the groups: Between June 17,and Aug 28,we randomly assigned 1: Plasma for biomarker analyses was obtained at frisc ii trial.